Physician profile
Carson Oostra
NPI 1417311952
$4,548.92
in general payments reported to CMS, 2019-2025
18 companies · $220 in 2025
The $220 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $436 · 2023: $2,121 · 2024: $1,651 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,500 · Food and Beverage: $1,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,500.49 |
| Food and Beverage | $1,490.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,449.21 | 2022-2024 | Evoque, Pascal |
| Abbott Laboratories | $1,217.47 | 2022-2023 | Mitraclip |
| Atricure, INC. | $133.17 | 2023-2025 | Synergy Ablation System |
| Novartis Pharmaceuticals Corporation | $128.67 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $128.62 | 2024-2025 | Lifevest |
| Astellas Pharma US INC | $99.99 | 2021 | |
| Abiomed | $90.06 | 2023-2025 | Impella |
| Medtronic, INC. | $45.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $44.62 | 2022-2025 | Camzyos |
| Amgen INC. | $31.36 | 2022-2025 | Repatha |
| Boston Scientific Corporation | $29.85 | 2024 | Watchman Flx |
| Heartflow, INC. | $29.56 | 2024 | |
| Chiesi USA, INC. | $23.40 | 2023 | Kengreal, Cleviprex |
| Scpharmaceuticals INC. | $23.31 | 2025 | |
| Aroa Biosurgery Incorporated | $22.95 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $21.88 | 2021 | |
| Novo Nordisk INC | $15.51 | 2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $14.29 | 2023 | Brilinta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carson Oostra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.